Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 3NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 27Myeloid 13Lymphoid 12Plasma cell 7Classical hematology 7CNS 7Sarcoma 6Dermatologic 3Other solid neoplasm 1Other neoplasm 1Genitourinary 1

Conditions

Unspecified Childhood Solid Tumor, Protocol Specific 1

Interventions

Cisplatin 28Irinotecan 18Gemcitabine 18Paclitaxel 14alvocidib 13Fluorouracil 11Oxaliplatin 10Cyclophosphamide 10Carboplatin 10Leucovorin 8Bortezomib 8Biopsy 8Taxes 7Radiotherapy 7Pemetrexed 7Magnetic Resonance Spectroscopy 7Doxorubicin 73-aminopyridine-2-carboxaldehyde thiosemicarbazone 7Specimen Handling 6tanespimycin 5Vorinostat 5LMB-100 5Early Intervention, Educational 5Bevacizumab 5temsirolimus 4sargramostim 4Sorafenib 4Sirolimus 4Platinum 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Busulfan × Other solid neoplasm × Clear all
NCT00436761 2013-12-18

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

National Cancer Institute (NCI)

Phase 1 Unknown
20 enrolled
Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡